T Cell Therapy of Patients with Advanced Renal Cell Carcinoma

  • Alfred E. Chang
  • Atsushi Aruga
  • Mark J. Cameron
  • Suyu Shu
Conference paper

Abstract

The feasibility of adoptive immunotherapy of cancer is based on two fundamental observations derived from experimental animal studies. The first of these observations is that tumor cells express unique antigens that can elicit an immune response in the syngeneic host. The other is that the immune rejection of tumors can be mediated by the adoptive transfer of appropriately sensitized lymphoid cells to the tumor bearing host. One of the significant obstacles in the application of adoptive immunotherapy to human malignancies has been the lack of reliable methods to identify and isolate tumor-reactive lymphoid cells from the tumor-bearing patient. Historically, human malignancies have been considered non-immunogenic by virtue of their spontaneous origins and thought to be incapable of eliciting a T cell immune response. These misconceptions have been proven incorrect by the recent molecular characterization of tumor antigens expressed on different human malignancies and their ability to act as recognition structures for sensitized T cells (1,2).

Keywords

Renal Cell Cancer Tumor Infiltrate Lymphocyte Autologous Tumor Adoptive Immunotherapy Chromium Release Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Van Der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647, 1991.Google Scholar
  2. 2.
    Kawakami Y, Zakut R, Topalian SL, Stotter H, and Rosenberg SA. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1 transfected melanomas. J Immunol 148: 638–643, 1992.PubMedGoogle Scholar
  3. 3.
    Mule JJ, Shu S, Schwarz SL, and Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487–1489, 1984.PubMedCrossRefGoogle Scholar
  4. 4.
    Mule JJ, Shu S, and Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 135: 64–652, 1985.Google Scholar
  5. 5.
    Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85: 622–632, 1993.PubMedCrossRefGoogle Scholar
  6. 6.
    McCabe MS, Stablein D, Hawkins MJ. The modified group C experience-Phase III randomized trials of IL-2 vs. IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol 10: 213, 1991 (abstract).Google Scholar
  7. 7.
    Rosenberg SA, Spiess P, and Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1321, 1986.PubMedCrossRefGoogle Scholar
  8. 8.
    Spiess PJ, Yang JC, and Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 79: 1067–1075, 1987.Google Scholar
  9. 9.
    Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in theimmunotherapy of patients with metastatic melanoma. New Engl. J. Med 319: 1676–1680, 1988.PubMedCrossRefGoogle Scholar
  10. 10.
    Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: Association with clinical response. J Natl Cancer Inst 83: 932–937, 1991.PubMedCrossRefGoogle Scholar
  11. 11.
    Bukowski RM, Sharfman W, Murthy S, et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res 51: 4199–4205, 1991.PubMedGoogle Scholar
  12. 12.
    Shu S, Chou T, and Rosenberg SA. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol 139: 295–304, 1987.PubMedGoogle Scholar
  13. 13.
    Chou T, Chang AE, and Shu S. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vivo sensitization. Culture requirements and characterization of immunologic specificity. J Immunol 140: 2453–2461, 1988.PubMedGoogle Scholar
  14. 14.
    Yoshizawa H, Chang AE, and Shu S. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin-2 activated tumor draining lymph node cells. Cancer Res 52: 1129–1136, 1992.PubMedGoogle Scholar
  15. 15.
    Yoshizawa H, Sakai K, Chang AE, and Shu S. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cellular Immunol 134: 473–479, 1991.CrossRefGoogle Scholar
  16. 16.
    Yoshizawa H, Chang AE, and Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147: 729–737, 1991.PubMedGoogle Scholar
  17. 17.
    Geiger JD, Wagner PD, Cameron MJ, Shu S, and Chang AE. Generation ofTcells reactive to the poorly immunogenic B 16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother 13: 153–165, 1993.CrossRefGoogle Scholar
  18. 18.
    Barth RJ, Mule JJ, Spiess PJ, and Rosenberg SA. Interferonyand tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173: 647–658, 1991.PubMedCrossRefGoogle Scholar
  19. 19.
    Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, and Shu S. Clinical observations on adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 53: 1043–1050, 1993.PubMedGoogle Scholar
  20. 20.
    Shu S, Knnock RA, Matsumura T., et al. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 152: 1277–1288, 1994.PubMedGoogle Scholar
  21. 21.
    Wahl WL, Strome SE, Nabel GJ, et al. Generation of therapeutic T lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene (in preparation).Google Scholar
  22. 22.
    Krauss JC, Strome SE, Chang AE and Shu S. Characteristics of the poorly immunogenic B16 melanoma genetically engineered to secrete IL-2 and IL-4. Proc Am Assoc Cane Res; 1994 (abstract).Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1995

Authors and Affiliations

  • Alfred E. Chang
    • 1
  • Atsushi Aruga
    • 1
  • Mark J. Cameron
    • 1
  • Suyu Shu
    • 1
  1. 1.Oncology Laboratory, Department of SurgeryUniversity of MichiganAnn ArborUSA

Personalised recommendations